跳至主要内容
临床试验/NCT02819310
NCT02819310已完成3 期

An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults

Braintree Laboratories24 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2016年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
330
试验地点
24
主要终点
% of Subjects With Treatment Emergent Adverse Events

研究概览

简要总结

The objective of this study is to evaluate the safety of chronic use of BLI400 laxative in constipated adults.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects at least 18 years of age
  • Constipated, defined by the following adapted ROME II definition:
  • Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months:
  • Straining during > 25% of defecations
  • Lumpy or hard stools in > 25% of defecations
  • Sensation of incomplete evacuation for > 25% of defecations
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

排除标准

  • Report loose (mushy) or water stools in the absence of laxative use for more than 25% of BMs during the 12 weeks before Visit 1
  • Meet the Rome II criteria for Irritable Bowel Syndrome
  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
  • Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1
  • Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1
  • Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 6
  • Subjects who are pregnant or lactating, or intend to become pregnant during the study
  • Subjects of childbearing potential who refuse a pregnancy test
  • Subjects who are allergic to any BLI400 component
  • Subjects taking narcotic analgesics or other medications known to cause constipation.
  • Subjects with clinically significant cardiac abnormalities identified at the Visit 1 ECG
  • Subjects with clinically significant laboratory abnormalities, deemed as a potential safety issue by the Investigator, may be discontinued at the Investigator's discretion.
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
  • Subjects with an active history of drug or alcohol abuse
  • Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1
  • Subjects who withdraw consent at any time prior to completion of Visit 1 procedures

研究组 & 干预措施

BLI400 Laxative

Experimental

BLI400 Laxative

干预措施: BLI400 Laxative (Drug)

结局指标

主要结局

% of Subjects With Treatment Emergent Adverse Events

时间窗: 12 months

% of subjects experiencing a treatment emergent adverse event during the 12 month treatment period

次要结局

未报告次要终点

研究者

发起方
Braintree Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验

An Open Label Study of Chronic Use of BLI400... | 临床试验